RxDoctor Payments Data

Frances Villarini, MD

Internal Medicine · San Juan, PRNPI 1437172186

Payments from drug & device makers

$1,740in general payments, 2019–2025

Across 79 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$941
  • Sanofi-aventis U.S. LLC$255
  • GSK$195
  • Boehringer Ingelheim$162
  • Merck$104
  • Johnson & Johnson$25
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$1,72899%
  • Gifts$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca41$941
Sanofi-aventis U.S. LLC12$255
GSK8$195
Boehringer Ingelheim9$162
Merck5$104
Johnson & Johnson1$25
E.r. Squibb & Sons, L.L.C.1$25
PBG Puerto Rico LLC1$20
Ascend Therapeutics US, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,740 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,257
Medicare patients
42
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol25$24,459
SynthroidLevothyroxine Sodium194$21,705
JanuviaSitagliptin Phosphate23$19,525
XareltoRivaroxaban24$18,917
JanumetSitagliptin Phos/Metformin Hcl16$18,128
JardianceEmpagliflozin11$9,244
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$6,596
Candesartan Cilexetil39$4,664
LantusInsulin Glargine,hum.Rec.Anlog26$4,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,523
Losartan Potassium205$3,368
Raloxifene Hcl28$3,153
Risedronate Sodium12$2,912
Metoprolol Succinate132$2,724
Gabapentin132$2,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$104$37,65339 claims
AstraZenecaFarxiga$941$24,45925 claims
Johnson & JohnsonXarelto$25$18,91724 claims
Boehringer IngelheimJardiance$162$9,24411 claims
Sanofi-aventis U.S. LLCLantus$255$4,22026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →